TechSeeker Profile

Sanofi (AKA: Aventis Pharmaceuticals)
Profile last edited on: 7/3/2019

NO Business Identifier is currently available for this company.
TS Type
Major Corp
Year Founded
Last Involved Year

Key People / Management

  Christopher A Viehbacher -- CEO

  Anjan Aralihalli --

  Ira C Baeringer --

  Mark Black --

  Sylvaine Cases -- External Innovation in the West Coast Office

  Hsien C Cheng --

  David R Compton --

  Hugues Corbeil --

  Marc G Corrado -- Director

  John E Cullity --

  George De Sanctis -- Director, Scouting & Partnering US, Prospective & Strategic Initiatives

  Alejandro Donoso -- Director, Technology Lice

  Gerd Fischer --

  David Ghesquiere -- Director, Global Business

  Sanjay Gupta --

  Daniel J Izzo --

  E Todd Johnson --

  Eric T Johnson -- Director, Financial Evalu

  Shabnam Kazmi --

  Sathapana Kongsamut --

  Shiv Krishnan -- Senior Director, Scouting & Partnering

  John Landy --

  Lewis K Lee -- Director, Portfolio & Pro

  Xiang Liao -- Sr. Manager Business Deve

  David Malek --

  Christine C Mayer -- Vice President

  Sridaran Natesan --

  Kevin P O'Brien --

  Daniel R Pascheles -- VP Corporate Development

  Bernd W Petermann -- Director, Global Business

  Margaret Petty --

  Thomas J Rice -- Director, U.S. New Produc

  Charles R Struby -- VP, New Products Commerci

  David Thorpe --

  Darcy B Toms -- Director, Global Business

  Benoit Vanasse --

  Tanja S Weber -- Director, Business Develo

  Thomas Wiatrowski --

  Carole A Wilmot -- Senior Director; US Busin

  Hugh Wilson -- Director-Corporate Develo

  Michael A Yeomans -- Vice President, Head of G

  John S Zawad -- VP, Aventis Capital

Location Information

174 Avenue De France Cedex 13
Paris, FR 75635
   (331) 537-74000

Public Profile

Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France. Formerly known as Sanofi-Aventis, Sanofi SA is a pharmaceutical company, contributes to enhancing life by providing an offering of medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company has products in the areas of thrombosis, cardiovascular, metabolic diseases, oncology, central nervous system, internal medicine, and vaccines. Its primary medicines include Lovenox/Clexane, Plavix/Iscover, Aprovel/Avapro/Karvea, Tritace/Triatec/Delix/Altace, Lantus, Amaryl/Amarel/Solosa, Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. The company?s vaccines principally include pediatric combination and poliomyelitis vaccines, influenza vaccines, meningitis/pneumonia vaccines, adult and adolescent booster vaccines, and travel and endemic vaccines. It has collaboration agreements principally with Novozymes, Dyax Corp., Oxford BioMedica, Regeneron, IDM, Zealand Pharma, UCB, and Crucell N.V., as well as partners, including Immunogen, Coley, Wayne State University, Innogenetics, Inserm, and Micromet Inc. The company also has an agreement with Drugs For Neglected Diseases Initiative (dndi) for the development, manufacturing, and distribution of fexinidazole, a drug for the treatment of human African trypanosomiasis; and a licensing agreement with Wellstat Therapeutics Corporation to develop, manufacture, and commercialize PN2034, an oral insulin sensitizer for the treatment of Type II diabetes. In addition, the company has interest in Merial Limited, an animal health company that provides a range of products to enhance the health, well-being, and performance of animals. It has a strategic antibody collaboration agreement with Regeneron Pharmaceuticals Inc. to discover, develop, and commercialize human therapeutic monoclonal antibodies. Sanofi-Aventis was founded in 1970 and is headquartered in Paris, France.

Extent of SBIR involvement

User Avatar